To include your compound in the COVID-19 Resource Center, submit it here.

Using magnets to fight cancer

FeRx Inc. is hoping that a single Phase II/III trial of its MTC-DOX magnetic targeted carrier formulation of doxorubicin will be sufficient for U.S. registration. The company is banking that its technology for site-specific administration to liver tumors will increase efficacy while reducing the serious cardiovascular

Read the full 467 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers